A Case Controlled Etiologic Study of Sarcoidosis (ACCESS) - Catalog
A Case Controlled Etiologic Study of Sarcoidosis (ACCESS)
HLB00300404a
ACCESS
ACC
False
True
True
Coded
False
Epidemiology Study
Open BioLINCC Study
Adult
2009-10-01
2009-10-01
2008-10-01
2005-12-21
June 1995 - March 2003
DLD
Lung
non-HIV
non-COVID
11211
0
No
No
No
Yes
Yes
Yes
Biospecimen research is restricted to studies related to sarcoidosis. Use of data is unrestricted.
Lung Diseases
Sarcoidosis
To determine the etiology of sarcoidosis by establishing a case control, multi-center study. In addition to etiology, this study also sought to examine socioeconomic variables and the clinical course of patients with sarcoidosis, including quality of life.
Sarcoidosis is a chronic granulomatous disorder of unknown cause that is characterized by activation of T-lymphocytes and macrophages. For many years sarcoidosis was presumed to be an atypical manifestation of tuberculosis because of the similarity between the inflammatory responses of the two diseases. However, as culture techniques became more widely employed to diagnose tuberculosis and it became less common, it became clear that sarcoidosis was not simply a variation of tuberculosis. Data on the etiology of sarcoidosis have come from diverse sources: in clinical investigations, alveolitis has been found to precede granulomatous inflammation; in case control studies, familial aggregation has been identified; and in case reports, recurrence of granulomatous inflammation has been observed after lung transplantation. The cause may not prove to be a single, known exposure. Interactions of exposures with genetic dispositions could have important implications for our understanding of immune responses as well as the pathogenesis of sarcoidosis.
736 patients with sarcoidosis enrolled within 6 months of diagnosis from 10 clinical centers in the U.S. Using the ACCESS sarcoidosis assessment system, organ involvement was determined for the whole group and for subgroups differentiated by sex, race, and age (<40 or 40 and older). Cases were matched with a control, and there was a two-year follow-up on cases. The ACCESS group proposed an instrument fo defining organ involvement in sarcoidosis. Biological specimens included DNA, plasma, and bronchoalveolar lavage samples were obtained. The data set includes 718 cases, 686 controls, and two-year follow-up data on 241 cases.
The initial presentation of sarcoidosis is related to sex, race and age, and it tends to remain stable over two years in the majority of patients. The etiology is probably multifactoral with both genetic and environmental factors contributing.
Bronchial Lavage
DNA
Peripheral Blood Mononuclear Cells
Plasma
The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.
-
Subjects
Cases: 718
Controls: 686
Last Modified: July 1, 2024, 2:30 p.m. -
Age
Case
Control
Total Subjects
18-29
80
75
155
30-39
247
222
469
40-49
214
224
438
50-59
129
118
247
>=60
48
47
95
Last Modified: July 1, 2024, 2:30 p.m. -
Sex
Case
Control
Total Subjects
Male
261
243
504
Female
457
443
900
Last Modified: July 1, 2024, 2:30 p.m. -
Race
Case
Control
Total Subjects
White
393
380
773
Black or African American
325
306
631
Last Modified: July 1, 2024, 2:30 p.m.
Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3.0 of the BioLINCC Handbook describes the components of the review process.
-
Material Types
Last Modified: Nov. 30, 2015, 10:16 a.m. -
General Freeze/Thaw Status
-
Visits (Vials)
10/31/2024
Plasma
DNA
PBMC
Bronchoalveolar Lavage (BAL)
Total Vials
14,488
29,389
1,394
633
45,904
Last Modified: Oct. 31, 2024, 9:24 a.m. -
Visits (Subjects)
10/31/2024
Plasma
Total number of subjects
Average volume (mL) per subject
1,424
11.87
DNA
Total number of subjects
Average mass (mg) per subject
1,426
20.61
PBMC
Total number of subjects
Average volume (mL) per subject
1,218
1.14
Bronchoalveolar Lavage (BAL)
Total number of subjects
Average volume (mL) per subject
73
8.67
Last Modified: Oct. 31, 2024, 9:24 a.m.